AMCP CEO Rosato Praises House Passage of 21st Century Cures Act

Alexandria, Va., July 10, 2015 — The Academy of Managed Care Pharmacy (AMCP) today issued a statement by AMCP CEO Edith A. Rosato, RPh, IOM in response to the House of Representative’s passage of H.R. 6, The 21st Century Cures Act. The bill includes increased funding for research and staffing for both the Food and Drug Administration and the National Institutes of Health. In addition, the legislation includes an important provision to prevent prescription drug abuse of opioids among at-risk Medicare beneficiaries. 

 
Rosato’s statement follows:

“The Academy is pleased that the 21st Century Cures Act (H.R.6) addresses the important subject of adequate funding for the Food and Drug Administration and the National Institutes of Health. These agencies are crucial to funding scientific research and finding new cures to disease. AMCP supports the role of pharmacists in outcomes research, including those processes by which health care systems identify treatment issues, conduct evaluations to measure results and improve care in defined patient populations. Pharmacists are well positioned to design and implement these programs and work collaboratively with prescribers and other health care professionals.

“H.R.6 also addresses prescription drug abuse, another important issue that is plaguing those at-risk in our senior population. With appropriate support, the Centers for Medicare and Medicaid Services (CMS) can combat fraud, waste and abuse, saving the taxpayers millions of dollars on an annual basis. Sec. 3141 would establish a drug management program to help Medicare beneficiaries at risk for opioid abuse – its inclusion is an important step in fighting the growing epidemic of opioid abuse.

“AMCP will continue to work with Congress and the CMS on establishing drug management programs for at-risk beneficiaries that replicate the successes of those in the Medicaid program and private sector.
 

The Academy has developed a detailed position on controlled substances in Part D, which is available here.